What's in Ranbaxy Laboratories Limited's pipeline?

Ranbaxy Laboratories Limited has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Ranbaxy Laboratories Limited's portfolio?

Top competitors by shared drug class: Organon and Co.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ranbaxy-laboratories-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Ranbaxy Laboratories Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ranbaxy Laboratories Limited pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ANTARA® (fenofibrate)	ANTARA® (fenofibrate)	marketed	Fibrate (PPARα agonist)	PPARα (Peroxisome proliferator-activated receptor alpha)	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Organon and Co · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ranbaxy Laboratories Limited:

Cite this brief

Drug Landscape (2026). Ranbaxy Laboratories Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ranbaxy-laboratories-limited. Accessed 2026-06-10.